Cargando…

Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors

Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern pose a challenge to the effectiveness of current vaccines. A vaccine that could prevent infection caused by known and future variants of concern as well as infection with pre-emergent sarbecoviruses (i.e., thos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Chee-Wah, Chia, Wan-Ni, Young, Barnaby E., Zhu, Feng, Lim, Beng-Lee, Sia, Wan-Rong, Thein, Tun-Linn, Chen, Mark I.-C., Leo, Yee-Sin, Lye, David C., Wang, Lin-Fa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422514/ https://www.ncbi.nlm.nih.gov/pubmed/34407341 http://dx.doi.org/10.1056/NEJMoa2108453

Ejemplares similares

Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor
por: Chia, Wan Ni, et al.
Publicado: (2023)

Differential escape of neutralizing antibodies by SARS-CoV-2 Omicron and pre-emergent sarbecoviruses
por: Wang, Lin-Fa, et al.
Publicado: (2022)

Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit
por: Hurlburt, Nicholas K., et al.
Publicado: (2022)

Superimmunity by pan-sarbecovirus nanobodies
por: Xiang, Yufei, et al.
Publicado: (2022)

Priming conditions shape breadth of neutralizing antibody responses to sarbecoviruses
por: Jia, Janice Zhirong, et al.
Publicado: (2022)

Utilities and Limitations of the World Health Organization 2009 Warning Signs for Adult Dengue Severity
por: Thein, Tun-Linn, et al.
Publicado: (2013)

Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians
por: Wang, Bei, et al.
Publicado: (2021)

Pan-sarbecovirus mAb protects from variants
por: Flemming, Alexandra
Publicado: (2021)

Differential Clinical Outcome of Dengue Infection among Patients with and without HIV Infection: A Matched Case–Control Study
por: Pang, Junxiong, et al.
Publicado: (2015)

Early clinical and laboratory risk factors of intensive care unit requirement during 2004–2008 dengue epidemics in Singapore: a matched case–control study
por: Pang, Junxiong, et al.
Publicado: (2014)

Differentiating coronavirus disease 2019 (COVID-19) from influenza and dengue
por: Thein, Tun-Linn, et al.
Publicado: (2021)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

Neutralizing Activity and SARS-CoV-2 Vaccine mRNA Persistence in Serum and Breastmilk After BNT162b2 Vaccination in Lactating Women
por: Yeo, Kee Thai, et al.
Publicado: (2022)

An interferon-integrated mucosal vaccine provides pan-sarbecovirus protection in small animal models
por: Yuen, Chun-Kit, et al.
Publicado: (2023)

Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies
por: Zhang, Fengwen, et al.
Publicado: (2023)

Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination
por: Adams, Lily E., et al.
Publicado: (2023)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Blood pressure trend in hospitalized adult dengue patients
por: Yeung, Wesley, et al.
Publicado: (2020)

Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2
por: Anderson, Danielle E., et al.
Publicado: (2020)

Neutralizing Antibody Response to Sarbecovirus Is Delayed in Sequential Heterologous Immunization
por: Lv, Huibin, et al.
Publicado: (2022)

Identifying Adult Dengue Patients at Low Risk for Clinically Significant Bleeding
por: Wong, Joshua G. X., et al.
Publicado: (2016)

The Significance of Prolonged and Saddleback Fever in Hospitalised Adult Dengue
por: Ng, Deborah HL, et al.
Publicado: (2016)

Long-Term Neutralizing Antibody Titers After BNT162b2 Vaccination in Hemodialysis Patients
por: Takazono, Takahiro, et al.
Publicado: (2023)

Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine
por: Coléon, Séverin, et al.
Publicado: (2022)

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
por: Cele, Sandile, et al.
Publicado: (2021)

Broad-spectrum pan-genus and pan-family virus vaccines
por: Tan, Chee Wah, et al.
Publicado: (2023)

Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses
por: Wang, Yingdan, et al.
Publicado: (2022)

Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody
por: Tortorici, M. Alejandra, et al.
Publicado: (2021)

Evaluation of neutralizing antibodies after vaccine BNT162b2: Preliminary data
por: Vietri, Maria Teresa, et al.
Publicado: (2022)

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
por: Renia, Laurent, et al.
Publicado: (2022)

A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs
por: Liu, Zezhong, et al.
Publicado: (2022)

Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry
por: Park, Young-Jun, et al.
Publicado: (2021)

An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses
por: Liu, Lihong, et al.
Publicado: (2022)

Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry
por: Park, Young-Jun, et al.
Publicado: (2022)

A broadly neutralizing nanobody targeting the highly conserved S2 subunit of sarbecoviruses
por: Wang, Xiaoyun, et al.
Publicado: (2023)

Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses
por: Radić, Laura, et al.
Publicado: (2023)

Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening
por: Yang, Xuehua, et al.
Publicado: (2023)

Epidemiological risk factors for adult dengue in Singapore: an 8-year nested test negative case control study
por: Yung, Chee Fu, et al.
Publicado: (2016)

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
por: Falsey, Ann R., et al.
Publicado: (2021)

Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation
por: Peled, Yael, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ufcjt2uj33o40l42kj7kqv5k04